1. Home
  2. CRCT vs AUPH Comparison

CRCT vs AUPH Comparison

Compare CRCT & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRCT
  • AUPH
  • Stock Information
  • Founded
  • CRCT 1969
  • AUPH 1993
  • Country
  • CRCT United States
  • AUPH Canada
  • Employees
  • CRCT N/A
  • AUPH N/A
  • Industry
  • CRCT Wholesale Distributors
  • AUPH Biotechnology: Pharmaceutical Preparations
  • Sector
  • CRCT Industrials
  • AUPH Health Care
  • Exchange
  • CRCT Nasdaq
  • AUPH Nasdaq
  • Market Cap
  • CRCT 1.0B
  • AUPH 999.8M
  • IPO Year
  • CRCT 2021
  • AUPH 1999
  • Fundamental
  • Price
  • CRCT $6.13
  • AUPH $8.00
  • Analyst Decision
  • CRCT Sell
  • AUPH Strong Buy
  • Analyst Count
  • CRCT 3
  • AUPH 2
  • Target Price
  • CRCT $4.52
  • AUPH $11.50
  • AVG Volume (30 Days)
  • CRCT 588.6K
  • AUPH 971.5K
  • Earning Date
  • CRCT 05-06-2025
  • AUPH 05-12-2025
  • Dividend Yield
  • CRCT 9.60%
  • AUPH N/A
  • EPS Growth
  • CRCT 6.92
  • AUPH N/A
  • EPS
  • CRCT 0.31
  • AUPH 0.04
  • Revenue
  • CRCT $707,780,000.00
  • AUPH $235,133,000.00
  • Revenue This Year
  • CRCT N/A
  • AUPH $11.86
  • Revenue Next Year
  • CRCT $2.06
  • AUPH $24.96
  • P/E Ratio
  • CRCT $20.18
  • AUPH $199.38
  • Revenue Growth
  • CRCT N/A
  • AUPH 33.97
  • 52 Week Low
  • CRCT $3.94
  • AUPH $4.98
  • 52 Week High
  • CRCT $8.40
  • AUPH $10.67
  • Technical
  • Relative Strength Index (RSI)
  • CRCT 68.87
  • AUPH 48.76
  • Support Level
  • CRCT $5.00
  • AUPH $7.89
  • Resistance Level
  • CRCT $6.58
  • AUPH $8.38
  • Average True Range (ATR)
  • CRCT 0.29
  • AUPH 0.24
  • MACD
  • CRCT 0.21
  • AUPH 0.01
  • Stochastic Oscillator
  • CRCT 81.17
  • AUPH 39.68

About CRCT Cricut Inc.

Cricut Inc designs and builds a creativity platform that enables users to turn ideas into professional-looking handmade goods. With its connected machines, design apps and accessories, and materials, the users create everything from personalized birthday cards, mugs and T-shirts to large-scale interior decorations. It has two segments including the Platform segment which derives revenue from monthly and annual subscription fees, purchases of digital content, and a minimal amount of the revenue allocated to unspecified future upgrades and enhancements related to the essential software and access to the Company's cloud-based services and Products segment which derives revenue from the sale of its connected machine hardware, and sale of craft, DIY, home decor products and extensions.

About AUPH Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

Share on Social Networks: